Rockwell chairman and CEO Robert Chioini said the patent gives additional protection to the method and pharmaceutical composition.
"Also, this patent further strengthens our overall IP portfolio for our SFP technology," Chioini added.
The company is conducting two Phase III prospective, randomized, placebo-controlled, multicenter studies for SFP called CRUISE-1 and CRUISE-2 to demonstrate efficacy and safety of SFP-iron delivered via dialysate to adult CKD patients requiring hemodialysis.
The mean change in hemoglobin from baseline is the primary efficacy end-point for both studies.